Free Medical Billing Audit

Substance Use & MOUD Billing Services

Substance use disorder billing — including medications for opioid use disorder (MOUD) — has rules no other specialty carries: opioid treatment programs are paid through weekly bundled codes, office-based treatment uses its own monthly bundles, drug testing is tightly scrutinized for frequency and medical necessity, and confidentiality rules govern how records move. The clinical model (an opioid treatment program versus office-based treatment) changes the entire billing structure, and getting that wrong means the claims never fit. Mednex Group supports SUD and MOUD billing as process and responsibility: matching the care model to the right bundle, authorization, defensible drug-testing claims, and denial work, all handled under the applicable confidentiality requirements. Mednex cannot promise payer decisions or reimbursement.

Open-plan office with white desks
On this page
  1. What substance use treatment billing involves
  2. Who this affects
  3. Common codes and what they usually mean
  4. OTP versus office-based treatment
  5. Drug testing: frequency and medical necessity
  6. Confidentiality and records handling
  7. Common denial patterns
  8. Investigation steps when claims go unpaid
  9. How Mednex works with SUD and MOUD providers
  10. Mednex and practice responsibilities
  11. Records and access needed
  12. Quality checks and exceptions
  13. How progress is measured
  14. What cannot be promised
  15. Sources to verify
  16. Frequently asked questions
  17. What do substance use treatment billing services include?
  18. What is the difference between OTP and office-based MOUD billing?
  19. Why do drug-testing claims get denied or audited?
  20. How are substance use treatment records handled?
  21. Does MOUD still require a special waiver to bill?
  22. How is SUD and MOUD billing priced?
  23. Next steps

What substance use treatment billing involves

SUD treatment is delivered in different settings with different payment models. Opioid treatment programs (OTPs) dispensing methadone or buprenorphine are generally paid through weekly bundled payments that cover the drug and the services together. Office-based opioid treatment (OBOT) in a physician practice uses monthly management bundles and standard E/M. Counseling, intensive outpatient, and partial hospitalization have their own levels of care and benefit rules. Drug testing supports treatment but is a known overutilization target. SUD billing is the work of matching each service to the correct model and code, authorizing what needs authorization, and keeping drug-testing claims defensible.

Who this affects

Opioid treatment programs, office-based MOUD providers, addiction medicine practices, behavioral health groups, and primary care practices that prescribe buprenorphine. With the removal of the separate waiver requirement for prescribing buprenorphine, more practices provide MOUD, and more of them hit billing problems they have not seen before — bundle selection, drug-testing denials, and confidentiality-compliant records handling.

Common codes and what they usually mean

Confirm current descriptors, bundle definitions, and payer policy before billing.

  • G2067–G2075 — weekly bundled payments for opioid treatment program services, varying by the medication and components included.
  • G2086 / G2087 / G2088 — office-based monthly bundles for management of opioid use disorder, including the initial and subsequent months and add-on counseling.
  • 99408 / 99409 — alcohol and substance use screening and brief intervention (SBIRT).
  • H0020 — methadone administration (used in certain program and payer contexts).
  • 80305–80307 — drug testing (presumptive and definitive), with definitive testing coded by the number of analytes.

The core decision is the care model: an OTP’s weekly bundle and an OBOT monthly bundle are not interchangeable, and billing an office practice as if it were an OTP (or vice versa) produces claims that do not fit the payer’s structure.

OTP versus office-based treatment

The distinction drives everything. An opioid treatment program is a specifically certified entity whose services are bundled into weekly payments. Office-based opioid treatment is delivered in a standard practice using monthly management bundles plus E/M and counseling. Each has enrollment and billing requirements the other does not, and a practice that is structured one way cannot bill as the other. Confirming the model and billing accordingly is the first step, and it is where the largest structural errors occur.

Drug testing: frequency and medical necessity

Drug testing is a legitimate part of SUD treatment and a frequent source of denials and audits because it has been overused industry-wide. Payers apply frequency limits and expect documentation tying each test to the patient’s stage of treatment and clinical need — presumptive versus definitive testing, the number of analytes, and the reason for the test all matter. Routine blanket testing without individualized justification is the pattern payers target. Defensible drug-testing billing documents why each test was ordered and keeps frequency within what the clinical picture supports.

Confidentiality and records handling

Records of SUD treatment are governed by heightened federal confidentiality rules that restrict how substance use treatment information is disclosed, beyond ordinary privacy requirements. This affects how claims, documentation, and appeals are handled — information cannot move the way it does for other specialties without the proper consents and safeguards. Billing for SUD treatment has to respect these rules, not treat the records like any other chart.

Common denial patterns

  • Wrong care-model billing — OTP weekly bundle vs OBOT monthly bundle mismatched to the setting.
  • Drug-testing frequency/medical necessity — tests beyond limits or without individualized justification.
  • Authorization — levels of care (IOP/PHP) or medications not authorized.
  • Bundle component errors — services billed separately that are included in a bundle.
  • Enrollment/credentialing — provider or program not enrolled correctly for the service.
  • Documentation — treatment plan and medical necessity not supporting the level of care.

Investigation steps when claims go unpaid

The check runs in order: confirm the care model and that the billed bundle matches it; confirm authorization for the level of care and medications; confirm drug-testing frequency and necessity are documented; confirm bundle components were not unbundled; then review enrollment and treatment-plan documentation — all handled under the confidentiality rules. SUD denials concentrate in model mismatch and drug testing, so those come first.

How Mednex works with SUD and MOUD providers

Mednex confirms the care model and bills the matching bundle, manages authorization for levels of care and medications, keeps drug-testing claims within defensible frequency and necessity, and handles records and appeals under the applicable confidentiality rules. Denials are worked to root cause and the practice gets reporting on denial reasons, drug-testing utilization, and authorization gaps. Mednex works inside the existing EHR and behavioral health system.

Mednex and practice responsibilities

Mednex does not provide treatment, prescribe, order tests, or decide medical necessity. Mednex confirms the billing model, manages authorization, keeps claims defensible, and works denials within the confidentiality framework. The practice owns the clinical care, the orders, the treatment plan, and the required consents. Mednex is not a law firm; confidentiality and audit questions that become legal matters are for the practice’s counsel.

Records and access needed

  • Access to the EHR and behavioral health documentation system, under the proper agreements.
  • Program certification or office-based model details.
  • Treatment plans and medical-necessity documentation by level of care.
  • Drug-testing orders and clinical justification.
  • The payer mix and SUD, MOUD, and drug-testing policies.

No protected health information is collected through this website. Substance use treatment records are handled under their heightened confidentiality requirements through a secure workflow and the appropriate agreements.

Quality checks and exceptions

Before submission, claims are checked for care-model match, authorization, defensible drug-testing frequency and necessity, and correct bundle components. Exceptions — a patient moving between levels of care, a drug-testing pattern near frequency limits, a model or enrollment question — are flagged for review.

How progress is measured

Performance is measured on clean-claim rate, drug-testing denial and utilization patterns, authorization capture, and denial reasons — not on a revenue promise. These show whether the gap is model, testing, or authorization.

What cannot be promised

  • That a payer will cover a given level of care, medication, or test frequency.
  • That a specific amount of revenue will result.
  • That drug testing beyond documented necessity will be paid.
  • That a model-mismatched claim can be made to fit after the fact.

Sources to verify

SUD and MOUD codes, bundles, drug-testing policies, and confidentiality rules change. Before relying on any statement here for a claim, verify against current primary sources: the Medicare Physician Fee Schedule and OTP payment guidance, SAMHSA and the applicable federal confidentiality regulations, the CMS Medicare Coverage Database, and the specific payer’s SUD and drug-testing policy.

Frequently asked questions

What do substance use treatment billing services include?

Confirming the care model and billing the matching bundle, managing authorization for levels of care and medications, keeping drug-testing claims defensible on frequency and necessity, submitting claims, and working denials under the applicable confidentiality rules.

What is the difference between OTP and office-based MOUD billing?

Opioid treatment programs are paid through weekly bundled codes that include the medication and services; office-based opioid treatment uses monthly management bundles plus E/M and counseling. The two models are not interchangeable, and billing one as the other causes denials.

Why do drug-testing claims get denied or audited?

Drug testing has been overused industry-wide, so payers apply frequency limits and expect each test tied to the patient’s treatment stage and clinical need. Routine blanket testing without individualized justification is a frequent denial and audit trigger.

How are substance use treatment records handled?

SUD treatment records are governed by heightened federal confidentiality rules that restrict disclosure beyond ordinary privacy requirements. Claims, documentation, and appeals are handled with the proper consents and safeguards.

Does MOUD still require a special waiver to bill?

The separate waiver requirement for prescribing buprenorphine was removed, so more practices now provide MOUD. Billing still depends on the correct model, authorization, and documentation, which is where new providers most often run into problems.

How is SUD and MOUD billing priced?

Pricing depends on the care model, volume, and drug-testing mix. Mednex reviews the model and a claim sample before proposing scope. Start with a free billing audit.

Next steps

If SUD claims deny on model mismatch, drug testing, or authorization, a free medical billing audit will show where. Mednex reviews a sample of SUD and MOUD claims and denials and sends a written summary, handled under the applicable confidentiality rules. No patient information is needed to begin. This pairs with mental health billing, medical billing, prior authorization, and denial management; or contact Mednex.


See where your revenue cycle stands

Request the free medical billing audit. You receive a written summary of findings and a walkthrough call. No obligation, and no patient information is needed to start.

Do not include patient names, insurance IDs or clinical details. If records are needed later, we set up a secure way to share them.